| VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia. | |
| | |
MedLine Citation:
|
PMID: 20842105 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
In chronic lymphocytic leukemia (CLL), overexpression of antiapoptotic B-cell leukemia/lymphoma 2 (BCL-2) family members contributes to leukemogenesis by interfering with apoptosis; BCL-2 expression also impairs vesicular stomatitis virus (VSV)-mediated oncolysis of primary CLL cells. In the effort to reverse resistance to VSV-mediated oncolysis, we combined VSV with obatoclax (GX15-070)-a small-molecule BCL-2 inhibitor currently in phase 2 clinical trials-and examined the molecular mechanisms governing the in vitro and in vivo antitumor efficiency of combining the two agents. In combination with VSV, obatoclax synergistically induced cell death in primary CLL samples and reduced tumor growth in severe combined immunodeficient (SCID) mice-bearing A20 lymphoma tumors. Mechanistically, the combination stimulated the mitochondrial apoptotic pathway, as reflected by caspase-3 and -9 cleavage, cytochrome c release and BAX translocation. Combination treatment triggered the release of BAX from BCL-2 and myeloid cell leukemia-1 (MCL-1) from BAK, whereas VSV infection induced NOXA expression and increased the formation of a novel BAX-NOXA heterodimer. Finally, NOXA was identified as an important inducer of VSV-obatoclax driven apoptosis via knockdown and overexpression of NOXA. These studies offer insight into the synergy between small-molecule BCL-2 inhibitors such as obatoclax and VSV as a combination strategy to overcome apoptosis resistance in CLL. |
| | |
Authors:
|
Sara Samuel; Vanessa F Tumilasci; Stephanie Oliere; Thi Liên-Anh Nguyên; April Shamy; John Bell; John Hiscott |
Related Documents
:
|
17627475 - Bcl-2 family members regulate anoxia-induced cell death. 8596025 - Differential regulation of bcl-2 and bcl-x by cd3, cd28, and the il-2 receptor in clone... 9596995 - A phosphatidylcholine phospholipase c inhibitor, d609, blocks interleukin-3 (il-3)-indu... 11396165 - Tgf beta 1 induces caspase-dependent but death-receptor independent apoptosis in lympho... 22837035 - Neurogenic inflammation and the peripheral nervous system in host defense and immunopat... 20158475 - Virulence mechanisms displayed by salmonella to impair dendritic cell function. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-09-14 |
Journal Detail:
|
Title: Molecular therapy : the journal of the American Society of Gene Therapy Volume: 18 ISSN: 1525-0024 ISO Abbreviation: Mol. Ther. Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-12-01 Completed Date: 2011-04-18 Revised Date: 2011-12-21 |
Medline Journal Info:
|
Nlm Unique ID: 100890581 Medline TA: Mol Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 2094-103 Citation Subset: IM |
Affiliation:
|
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antineoplastic Agents / pharmacology Apoptosis Cell Line, Tumor Combined Modality Therapy Disease Models, Animal Female Gene Therapy Humans Leukemia, Lymphocytic, Chronic, B-Cell / therapy* Mice Mice, SCID Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors* Pyrroles / pharmacology* Reverse Transcriptase Polymerase Chain Reaction Vesiculovirus* / physiology |
| Grant Support | |
ID/Acronym/Agency:
|
//Canadian Institutes of Health Research |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Proto-Oncogene Proteins c-bcl-2; 0/Pyrroles; 0/obatoclax |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Paracrine factors of multipotent stromal cells ameliorate lung injury in an elastase-induced emphyse...
Next Document: T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms.